Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia

Abstract: Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), complete remission rates are close to 60% to 70%, and relapses occur in >40% of cases. Here, we studied the molecula...

Full description

Saved in:
Bibliographic Details
Main Authors: Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Hervé Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Pierre Peterlin, Simon Bouzy, Pascale Flandrin-Gresta, Emmanuelle Tavernier, Martin Carre, Sylvie Tondeur, Lamya Haddaoui, Raphael Itzykson, Sarah Bertoli, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Christian Récher, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924006165
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952924006165

Similar Items